Literature DB >> 2123913

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration.

J Fevery1, E Van Cutsem, F Nevens, W Van Steenbergen, R Verberckmoes, J De Groote.   

Abstract

Four consecutive patients with alcoholic cirrhosis and hepatorenal syndrome were treated with misoprostol, a synthetic methylester prostaglandin E1 analogue at twice the dosage advocated for anti-ulcer therapy (i.e., 0.4 mg four times per day orally) and albumin infusions. The mean urinary output obtained over the 3 days preceding misoprostol administration was 250, 315, 550 and 195 ml per 24 h, respectively, in the four patients, despite adequate volume expansion by plasma albumin to reach normal or high central venous pressure. Diuresis increased to 1450, 2440, 925 and 1300 ml, respectively, on days 2-4 after onset of therapy. Serum creatinine levels were 71, 51, 33 and 35 mg/l before and dropped to 26, 21, 13 and 17 mg/l during treatment. All patients had hyponatraemia (117-128 mequiv/l) which normalized, although they were continued on a low sodium intake of less than 10 mequiv per 24 h. Urinary sodium excretion increased from 0.4-3 mmol per 24 h, to 15-40 in the first two cases and only slightly to 3-5 in the last two patients. Three patients died after 10, 30 and 40 days due to oesophageal bleeding, encephalopathy or pulmonary infection, whereas one patient underwent an orthotopic liver transplantation when her serum creatinine attained a level of 13 mg/l. In the first patient, hepatorenal syndrome recurred 10 days after stopping the misoprostol treatment. High doses of misoprostol in the presence of adequate volume expansion thus seem to produce marked diuresis and creatininuria as well as mild natriuresis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123913     DOI: 10.1016/0168-8278(90)90106-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

2.  Hepatorenal Syndrome.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-12

Review 3.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

Review 4.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

5.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Authors:  K A Brensing; J Textor; J Perz; P Schiedermaier; P Raab; H Strunk; H U Klehr; H J Kramer; U Spengler; H Schild; T Sauerbruch
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

6.  Renal haemodynamics and function following partial portal decompression.

Authors:  Sharona Ross; Donald Thometz; Francesco Serafini; Mark Bloomston; Connor Morton; Emmanuel Zervos; Alexander Rosemurgy
Journal:  HPB (Oxford)       Date:  2009-05       Impact factor: 3.647

Review 7.  Kidneys in chronic liver diseases.

Authors:  Marek Hartleb; Krzysztof Gutkowski
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

Review 8.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.